News

The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.

A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.

According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.

On March 6, 2024, the FDA approved inotuzumab ozogamicin for pediatric patients with relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.

According to a phase 3 trial, adding daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy yielded beneficial outcomes among transplantation-eligible patients with newly diagnosed multiple...

Orly Leiva, MD, and colleagues examined cardiovascular outcomes for patients with myeloproliferative neoplasms, highlighting increased risks for patients with myelofibrosis.

The FDA has approved belzutifan, an HIF-2α inhibitor, for the treatment of advanced kidney cancer, based on promising results from the phase 3 LITESPARK-005 trial led by Dana-Farber researchers.

Two leading oncology care organizations, the National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA), have joined forces to create ONCare Alliance, LLC.

Momelotinib displayed clinically meaningful symptom benefits among patients with myelofibrosis, according to a study that analyzed the appropriateness of the symptom change threshold used in the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials.

The addition of parsaclisib to ruxolitinib treatment decreased spleen volume, improved symptom scores, and demonstrated acceptable safety among patients with primary or secondary myelofibrosis, according to a phase 2 study.